Periodic Reporting for period 3 - SENCAN (Senescence therapy for cancer)
Période du rapport: 2021-10-01 au 2023-03-31
In 2019 the Bernards laboratory published the first proof of concept of this “one-two punch” approach for the treatment of liver cancer. The main aims of the SENCAN program are to find drugs that induce this state of dormancy in the cancer cells and to find ways to kill these dormant cancer cells. In the first half of the grant we have made major progress in developing new drugs that would enable this new therapeutic approach. We collaborate with several pharmaceutical companies to
We have also identified tools to kill these senescent cancer cells. Again, we have identified drugs that were used in the clinic for other indications, which again shortens the time required to bring these discoveries to the clinic.
Finally, we have demonstrated the utility of the “one-two punch” approach to cancer therapy that exploits the sequential induction of senescence followed by killing of senescent cancer cells in multiple animal models of cancer. The leader of the SENCAN program has established a company to bring these discoveries to the clinic as soon as possible.
We aim to have the first one two punch cancer therapy ready for clinical testing by the end of the SENCAN project in the fall of 2023.